Table 3 Associations of YSM one unit, metabolomic signature per SD increment with aging biomarkers by baseline age and MHT use status

From: Years since menopause and its metabolomic signature with biological aging in women at midlife: a population-based study

 

YSM

Metabolic signature

 

OR (95%CI)

P

OR (95%CI)

P

Baseline age < = 60

 Long TL

0.94 (0.92, 0.97)

<0.001

0.94 (0.92, 0.97)

<0.001

 High AL

1.09 (1.05, 1.12)

<0.001

1.52 (1.47, 1.57)

<0.001

 High PA

0.96 (0.88, 1.06)

0.429

2.40 (2.20, 2.61)

<0.001

Baseline age > 60

 Long TL

0.89 (0.87, 0.91)

<0.001

0.93 (0.90, 0.96)

<0.001

 High AL

1.07 (1.04, 1.10)

<0.001

1.53 (1.48, 1.58)

<0.001

 High PA

1.07 (0.99, 1.15)

0.095

2.22 (2.05, 2.42)

<0.001

MHT (No)

 Long TL

0.90 (0.88, 0.93)

<0.001

0.95 (0.93, 0.98)

<0.001

 High AL

1.10 (1.06, 1.13)

<0.001

1.53 (1.48, 1.57)

<0.001

 High PA

1.03 (0.95, 1.12)

0.521

2.33 (2.15, 2.53)

<0.001

MHT (Yes)

 Long TL

0.94 (0.92, 0.97)

<0.001

0.93 (0.90, 0.95)

<0.001

 High AL

1.05 (1.02, 1.09)

<0.001

1.52 (1.47, 1.58)

<0.001

 High PA

1.00 (0.92, 1.09)

0.987

2.27 (2.08, 2.48)

<0.001

  1. OR Odds Ratio, CI Confidence Interval, TL Telomere Length, AL Allostatic Load, PA PhenoAge, MHT menopausal hormone therapy.
Back to article page